RxDoctor Payments Data

Jessica Goza, NP

Primary Care · Los Gatos, CANPI 1649710476

Payments from drug & device makers

$2,281in general payments, 2019–2025

Across 81 payments — averaging $28.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$255
  • Saluda Medical Americas, Inc.$186
  • Si-bone, Inc.$134
  • Biotronik NRO, Inc.$106
  • Biohaven Pharmaceutical Holding Company Ltd.$87
  • plus $165 from 3 others

What the payments were for

  • Food & beverage$2,281100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,281 in reported general payments places this provider in the 85th percentile of 706 primary care providers in California.

See all primary care providers in California

Medicare billing

Part B allowed, 2024
$104,069
Medicare patients
160
Services billed
6,152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate62$91,056
BotoxOnabotulinumtoxina30$38,724
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen643$17,806
BelbucaBuprenorphine Hcl13$13,492
Aimovig AutoinjectorErenumab-Aooe15$12,532
Emgality PenGalcanezumab-Gnlm17$12,326
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl45$9,055
Oxycodone Hcl600$7,671
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen253$6,394
Pregabalin289$6,347
Lidocaine60$6,265
Buprenorphine Hcl87$3,977
Gabapentin174$3,683
Cyclobenzaprine Hcl160$2,030
Diclofenac Sodium30$1,794

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$255$91,05662 claims
AbbVieBotox$1,348$38,72430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 706 primary care providers in California.

Other primary care in Los Gatos

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →